Prescribing Information for Pluvicto®▼(lutetium [177Lu] vipivotide tetraxetan) can be found here.

Prescribing Information for LUTATHERA® (lutetium [177Lu] oxodotreotide) can be found here.

  • Welcome to the RLT Hub. Image of a scientist looking at a 3d model of peptide receptor radionuclide therapy.
    Welcome to the RLT Hub
    The RLT Hub was developed by Novartis Pharmaceuticals UK Ltd, for UK healthcare professionals only. The platform provides information on Radioligand Therapy (RLT) and the management of eligible patients with neuroendocrine tumours (NET) and the management of eligible patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC).

Pluvicto®▼ is indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy or who are not medically suitable for taxanes.1

LUTATHERA® is indicated for the treatment of unresectable or metastatic, progressive, well-differentiated (G1 and G2), somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adults.2

The RLT Hub is your guide to understanding GEP-NETs, PSMA-positive mCRPC and RLT

The RLT Hub was developed by Novartis Pharmaceuticals UK Ltd, for UK healthcare professionals only. The platform provides information on RLT and the management of eligible patients with NET and the management of eligible patients with PSMA-positive mCRPC.

Site features

This site provides you with the relevant information and resources to guide your knowledge and understanding of GEP-NET, PSMA-positive mCRPC and RLT.

Clinical information on LUTATHERA® and GEP-NETs practical resources for UK healthcare professionals.
This information is intended for healthcare professionals in the UK only.

AR, androgen receptor; GEP, gastroenteropancreatic; mCRPC, metastatic castration-resistant prostate cancer; NET, neuroendocrine tumour; PSMA, prostate-specific membrane antigen; RLT, radioligand therapy.

References

  1. Pluvicto® (lutetium [177Lu] vipivotide tetraxetan) Summary of Product Characteristics.
  2. LUTATHERA® (lutetium [177Lu] oxodotreotide) Summary of Product Characteristics.
UK | March 2025 | FA-11330968
×

Ask Speakers

×

Medical Information Request